HBK Investments’s The Oncology Institute Warrant TOIIW Stock Holding History

HBK Investments’s Portfolio TOIIW Stock Details TOIIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-14,000	Closed	-$10K	–	820
2021 Q4	$10K	Buy	+14,000	New	+$17.3K	﹤0.01%	699

Other funds holding TOIIW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

HBK Investments's TOIIW Position: Q1 2022 in Review

HBK Investments sold out of The Oncology Institute Warrant (TOIIW) in Q1 2022, closing a stake of 14,000 shares — an estimated $10K sold.

HBK Investments first reported a position in TOIIW in Q4 2021 and held it in 1 quarter. The position peaked at $10K in Q4 2021. 12 funds tracked by Wall St. Rank hold TOIIW as of Q1 2022.

HBK Investments reported no remaining The Oncology Institute Warrant position as of Q1 2022 after selling out during the quarter.
HBK Investments sold 14,000 The Oncology Institute Warrant shares in Q1 2022, an estimated $10K.
HBK Investments first reported a position in The Oncology Institute Warrant in Q4 2021 and held it in 1 quarter.
HBK Investments's The Oncology Institute Warrant position peaked at $10K in Q4 2021.
12 funds tracked by Wall St. Rank held The Oncology Institute Warrant as of Q1 2022.

Based on HBK Investments's 13F filing for Q1 2022, filed 16 May 2022.